JP2003515533A5 - - Google Patents

Download PDF

Info

Publication number
JP2003515533A5
JP2003515533A5 JP2001537359A JP2001537359A JP2003515533A5 JP 2003515533 A5 JP2003515533 A5 JP 2003515533A5 JP 2001537359 A JP2001537359 A JP 2001537359A JP 2001537359 A JP2001537359 A JP 2001537359A JP 2003515533 A5 JP2003515533 A5 JP 2003515533A5
Authority
JP
Japan
Prior art keywords
hemoglobin
mammal
mutations
kilodaltons
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001537359A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003515533A (ja
JP5099951B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/030857 external-priority patent/WO2001034648A1/en
Publication of JP2003515533A publication Critical patent/JP2003515533A/ja
Publication of JP2003515533A5 publication Critical patent/JP2003515533A5/ja
Application granted granted Critical
Publication of JP5099951B2 publication Critical patent/JP5099951B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001537359A 1999-11-12 2000-11-10 副作用が減少されたヘモグロビン組成物 Expired - Fee Related JP5099951B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16528999P 1999-11-12 1999-11-12
US60/165,289 1999-11-12
PCT/US2000/030857 WO2001034648A1 (en) 1999-11-12 2000-11-10 Reduced side-effect hemoglobin compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011030290A Division JP2011098985A (ja) 1999-11-12 2011-02-15 副作用が減少されたヘモグロビン組成物

Publications (3)

Publication Number Publication Date
JP2003515533A JP2003515533A (ja) 2003-05-07
JP2003515533A5 true JP2003515533A5 (enExample) 2007-12-27
JP5099951B2 JP5099951B2 (ja) 2012-12-19

Family

ID=22598286

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001537359A Expired - Fee Related JP5099951B2 (ja) 1999-11-12 2000-11-10 副作用が減少されたヘモグロビン組成物
JP2011030290A Pending JP2011098985A (ja) 1999-11-12 2011-02-15 副作用が減少されたヘモグロビン組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011030290A Pending JP2011098985A (ja) 1999-11-12 2011-02-15 副作用が減少されたヘモグロビン組成物

Country Status (8)

Country Link
US (2) US6670323B1 (enExample)
EP (2) EP2292657A1 (enExample)
JP (2) JP5099951B2 (enExample)
AU (1) AU784195B2 (enExample)
CA (1) CA2391226A1 (enExample)
NO (1) NO20022229L (enExample)
WO (1) WO2001034648A1 (enExample)
ZA (1) ZA200203817B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670323B1 (en) * 1999-11-12 2003-12-30 Baxter International, Inc. Reduced side-effect hemoglobin compositions
DE10224750A1 (de) 2002-06-04 2003-12-24 Fresenius Medical Care De Gmbh Vorrichtung zur Behandlung einer medizinischen Flüssigkeit
US7092752B2 (en) * 2002-07-27 2006-08-15 Sheng-Xing Ma Skin acupoint/meridian nitric oxide collection kit and method thereof
US9138707B2 (en) * 2002-12-10 2015-09-22 Sy Kimball Portable, nitric oxide generator
EP1449535B1 (en) * 2003-02-18 2006-05-03 Clinique La Prairie Research SA Compositions comprising fetal hemoglobin and bacterial endotoxin and optionally additional fetal liver components
ES2347805T3 (es) * 2004-08-31 2010-11-04 Sangart, Inc. Metodos para aumentar la estabilidad hemodinamica usando composiciones que transportan oxigeno.
US7976866B2 (en) * 2004-12-06 2011-07-12 Opremcak E Mitchel Bandage and method for vital bleaching of skin
US7935074B2 (en) 2005-02-28 2011-05-03 Fresenius Medical Care Holdings, Inc. Cassette system for peritoneal dialysis machine
US8071546B2 (en) * 2005-06-10 2011-12-06 La Jolla Bioengineering Institute Uses of pegylated albumin
US8741832B2 (en) * 2005-06-10 2014-06-03 Albert Einstein College Of Medicine Of Yeshiva University Pegylated albumin and uses thereof
US8197231B2 (en) 2005-07-13 2012-06-12 Purity Solutions Llc Diaphragm pump and related methods
US9649467B2 (en) 2008-01-31 2017-05-16 Syk Technologies, Llc Nitric oxide reactor and distributor apparatus and method
US8720436B2 (en) * 2008-01-31 2014-05-13 Genosys, Inc. Nitric oxide gel apparatus and method
US8434475B2 (en) 2008-01-31 2013-05-07 Genosys, Inc. Nitric oxide reactor and distributor apparatus and method
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
US8501090B2 (en) * 2008-03-24 2013-08-06 Christian S. Minton Anti-microbial gas apparatus and method
US8192401B2 (en) 2009-03-20 2012-06-05 Fresenius Medical Care Holdings, Inc. Medical fluid pump systems and related components and methods
EP2453946B1 (en) 2009-07-15 2013-02-13 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems
US8720913B2 (en) 2009-08-11 2014-05-13 Fresenius Medical Care Holdings, Inc. Portable peritoneal dialysis carts and related systems
US8685467B2 (en) 2010-08-03 2014-04-01 J. W. Randolph Miller Nitric oxide generation, dilution, and topical application apparatus and method
US8609815B2 (en) * 2010-09-02 2013-12-17 Sangart, Inc. Methods for preparing stable deoxygenated PEG-hemoglobin conjugate solutions comprising an antioxidant
DE102010053973A1 (de) 2010-12-09 2012-06-14 Fresenius Medical Care Deutschland Gmbh Medizinisches Gerät mit einer Heizung
US9694125B2 (en) 2010-12-20 2017-07-04 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US9624915B2 (en) 2011-03-09 2017-04-18 Fresenius Medical Care Holdings, Inc. Medical fluid delivery sets and related systems and methods
CN103648540B (zh) 2011-04-21 2016-06-01 弗雷塞尼斯医疗保健控股公司 医疗流体泵送系统及相关装置和方法
ES2432075T3 (es) 2011-07-23 2013-11-29 Sastomed Gmbh Espray para heridas
BR112014007029A2 (pt) 2011-09-23 2017-04-11 Bluebird Bio Inc métodos aperfeiçoados de terapia gênica
MX359398B (es) 2011-09-30 2018-09-27 Bluebird Bio Inc Compuestos para transduccion viral mejorada.
US9186449B2 (en) 2011-11-01 2015-11-17 Fresenius Medical Care Holdings, Inc. Dialysis machine support assemblies and related systems and methods
IN2014MN02089A (enExample) * 2012-03-20 2015-09-11 Einstein Coll Med
US20130261412A1 (en) * 2012-03-28 2013-10-03 II Robert Lawrence Reed System and method for managing fluid levels in patients based upon creatinine clearance
US9610392B2 (en) 2012-06-08 2017-04-04 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US9500188B2 (en) 2012-06-11 2016-11-22 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
JP2014062050A (ja) * 2012-09-19 2014-04-10 Fujifilm Corp 多価官能マレイミド系重合性化合物、これを含む硬化組成物およびインク組成物
US9561323B2 (en) 2013-03-14 2017-02-07 Fresenius Medical Care Holdings, Inc. Medical fluid cassette leak detection methods and devices
US10517817B2 (en) 2013-05-09 2019-12-31 Syk Technologies, Llc Deep topical systemic nitric oxide therapy apparatus and method
US10117985B2 (en) 2013-08-21 2018-11-06 Fresenius Medical Care Holdings, Inc. Determining a volume of medical fluid pumped into or out of a medical fluid cassette
TWI666319B (zh) 2014-08-12 2019-07-21 美商巴克斯歐塔公司 在分泌ｆｕｒｉｎ之哺乳動物表現系統中生產經完全加工且具功能性之因子Ｘ
EP4400101A1 (en) 2016-01-27 2024-07-17 SYK Technologies, LLC Nitric oxide topical application apparatus and methods
EP3413896B1 (en) 2016-02-12 2021-03-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
CA3014078A1 (en) 2016-02-12 2017-08-17 Bluebird Bio, Inc. Vcn enhancer compositions and methods of using the same
JP7387597B2 (ja) 2017-07-18 2023-11-28 ヴァーテック・バイオ・インコーポレイテッド ヘモグロビンを含む代用血液及び作製方法
GB201721503D0 (en) * 2017-12-20 2018-01-31 Univ Essex Modified globin proteins
US10752672B1 (en) * 2019-02-01 2020-08-25 Cheer Global Limited Recombinant hemoglobins and methods of preparation and use thereof
JP7593609B2 (ja) * 2020-02-28 2024-12-03 学校法人 中央大学 ヘモグロビン微粒子及び人工酸素運搬体
US12459820B2 (en) 2020-06-11 2025-11-04 J. W. Randolph Miller Stabilized and NO2-inhibited nitric oxide generating gels for inhaled nitric oxide therapy
WO2022184005A1 (en) 2021-03-01 2022-09-09 Billion King International Limited Thiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof
EP4402242A4 (en) * 2021-09-17 2025-08-06 Univ Yale METHODS, SYSTEMS AND COMPOSITIONS FOR RESTORING AND PRESERVING INTACT ORGANS IN A MAMMAL
CN115317595A (zh) * 2021-09-27 2022-11-11 中国人民解放军军事科学院军事医学研究院 一种聚乙二醇化牛血红蛋白氧载体及其制备方法与应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3525272A (en) 1967-10-20 1970-08-25 Westinghouse Air Brake Co Multiposition control handle having detent means
DE2449885C3 (de) 1974-10-21 1980-04-30 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat
US4061736A (en) 1975-02-02 1977-12-06 Alza Corporation Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin
US4001200A (en) 1975-02-27 1977-01-04 Alza Corporation Novel polymerized, cross-linked, stromal-free hemoglobin
US4001401A (en) 1975-02-02 1977-01-04 Alza Corporation Blood substitute and blood plasma expander comprising polyhemoglobin
US4053590A (en) 1975-02-27 1977-10-11 Alza Corporation Compositions of matter comprising macromolecular hemoglobin
US4473496A (en) 1981-09-14 1984-09-25 The United States Of America As Represented By The Secretary Of The Army Intramolecularly crosslinked hemoglobin
DE3144705C2 (de) 1981-11-11 1983-12-08 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat
US4529719A (en) 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4600531A (en) 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
US4598064A (en) 1984-06-27 1986-07-01 University Of Iowa Research Foundation Alpha-alpha cross-linked hemoglobins
US4584130A (en) 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4868119A (en) 1986-12-11 1989-09-19 Genetics Institute, Inc. Hematopoietic growth factors
US4826811A (en) 1986-06-20 1989-05-02 Northfield Laboratories, Inc. Acellular red blood cell substitute
US5032676A (en) 1986-10-14 1991-07-16 Immunex Corporation Nonglycosylated analogs of human colony stimulating factors
DE3636590A1 (de) 1986-10-28 1988-05-26 Braun Melsungen Ag Blutersatzmittel
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
OA09736A (en) 1987-02-18 1993-11-30 Schering Biotech Corp "Human interleukin-3 and muteins thereof".
GB8711614D0 (en) 1987-05-16 1987-06-24 Medical Res Council Proteins
EP0561245A1 (en) * 1987-05-16 1993-09-22 Somatogenetics International, Inc. Blood substitutes comprising recombinant hemoglobin
JP2562840B2 (ja) 1988-08-01 1996-12-11 富士通株式会社 電界効果トランジスタ
IL87707A (en) 1988-09-08 1994-06-24 Technion Inst For Research And Hemoglobin-based blood substitute substantially similar to human blood and method for preparation thereof
US5545727A (en) * 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
US5844090A (en) 1994-05-09 1998-12-01 Somatogen, Inc. Modified hemoglobin-like compounds
US5173426A (en) 1989-10-06 1992-12-22 Yale University DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin
AU6541090A (en) 1989-10-16 1991-05-16 Amgen, Inc. Stem cell factor
US5478806A (en) 1989-11-22 1995-12-26 Enzon, Inc. Enhancement of antitumor therapy with hemoglobin-based conjugates
EP0459788A3 (en) 1990-06-01 1992-01-22 Common Services Agency Modified proteins and methods of producing same
WO1992020369A1 (en) 1991-05-14 1992-11-26 Dana Farber Cancer Institute Use of hemoglobin in a method for the treatment of tumors with chemotherapeutic agents
US5250665A (en) 1991-05-31 1993-10-05 The University Of Toronto Innovations Foundation Specifically β-β cross-linked hemoglobins and method of preparation
US5334706A (en) 1992-01-30 1994-08-02 Baxter International Administration of low dose hemoglobin to increase perfusion
IL106401A (en) 1992-08-07 1997-02-18 Donnelley & Sons Co Method and system for converting bitmap data into page definition language commands
US5840851A (en) 1993-07-23 1998-11-24 Plomer; J. Jeffrey Purification of hemoglobin
TW381022B (en) * 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
US5665869A (en) 1993-11-15 1997-09-09 Somatogen, Inc. Method for the rapid removal of protoporphyrin from protoporphyrin IX-containing solutions of hemoglobin
US5559907A (en) 1994-02-17 1996-09-24 Lucent Technologies Inc. Method of controlling polarization properties of a photo-induced device in an optical waveguide and method of investigating structure of an optical waveguide
US5631219A (en) 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US5585484A (en) 1995-04-19 1996-12-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Hemoglobin crosslinkers
US5733869A (en) * 1995-10-06 1998-03-31 Baxter International, Inc. Therapeutic administration of hemoglobin in cardiac arrest
AU4661797A (en) 1996-10-21 1998-05-15 Baxter International Inc. Therapeutic use of hemoglobin to treat head injury
WO1998050430A2 (en) 1997-05-02 1998-11-12 Somatogen, Inc. Hemoglobin mutants with increased soluble expression and/or reduced nitric oxide scavenging
US6670323B1 (en) * 1999-11-12 2003-12-30 Baxter International, Inc. Reduced side-effect hemoglobin compositions
EP2340681B1 (en) 2008-09-25 2014-11-12 Nokia Corporation Synchronization for device-to-device communication
US9005548B2 (en) 2009-02-25 2015-04-14 California Institute Of Technology Methods for fabricating high aspect ratio probes and deforming high aspect ratio nanopillars and micropillars
JP5963422B2 (ja) 2010-12-17 2016-08-03 キヤノン株式会社 撮像装置、表示装置、コンピュータプログラムおよび立体像表示システム

Similar Documents

Publication Publication Date Title
JP2003515533A5 (enExample)
JP3122128B2 (ja) ペプチド製剤
TW434259B (en) Acylated insulin analogs
ES2325777T3 (es) Uso de glp-1 o analogos en el tratamiento de accidente cerebrovascular.
JP5099951B2 (ja) 副作用が減少されたヘモグロビン組成物
EP2349310B1 (en) Polypeptide for treating or preventing adhesions
JP4173913B2 (ja) Ｏｂタンパク質組成物を用いて血中脂質レベルを減少させ又は減少した血中脂質レベルを維持する方法
JP6755175B2 (ja) インスリン投薬レジメン
ES2260916T3 (es) Preparacion en polvo para administracion a traves de la mucosa que contiene una medicina polimerica.
ES2217327T3 (es) Proteina ob para aumentar la masa de tejido magro.
JP2005526126A (ja) インスリンアスパルト及びインスリンデテミアを含む可溶性製剤
JPH06504286A (ja) 人ｉｇｆ−ｉの利用方法
EP2640411B1 (en) Interleukin-2 by subligual administration for use in the treatment of inflammation
TW201109034A (en) Hemoglobin compositions
US5900402A (en) Method of reducing side effects associated with administration of oxygen-carrying proteins
D’Souza et al. Nasal insulin gel as an alternate to parenteral insulin: formulation, preclinical, and clinical studies
TWI445544B (zh) 增進血管形成之組合物及方法
JP2003500456A (ja) 角質細胞増殖因子−２製剤
JP4726797B2 (ja) 消耗症に罹患している患者の治療における成長ホルモン放出因子類似体の使用
US4654324A (en) Human proinsulin pharmaceutical formulations
JP2010163457A (ja) 脈管形成に有効な単位用量のｆｇｆ−２および使用方法
JP2024524273A (ja) マズチドの使用
JP2002534479A5 (enExample)
JP2001501619A (ja) ｍｐｌリガンドを含有する医薬組成物
US4652547A (en) Pharmaceutical formulations comprising human insulin and human proinsulin